Difference between revisions of "Brana I, et al. Br. J. Cancer (2014) cited as Ref 581 in DOI: 10.1038/s41392-020-0110-5 (Q9844)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: title (P93): A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206 the mTOR inhibitor ridaforolimus or the NOTCH inhibitor MK-0752 in patients wit...)
(‎Created claim: Page(s) (P105): 1932-1944, #quickstatements; #temporary_batch_1590074839150)
 
Property / Page(s)
 +
1932-1944
Property / Page(s): 1932-1944 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Brana I, et al. Br. J. Cancer (2014) cited as Ref 581 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Brana I
    0 references
    0 references
    2014
    0 references
    Br. J. Cancer
    0 references
    111
    0 references
    A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206 the mTOR inhibitor ridaforolimus or the NOTCH inhibitor MK-0752 in patients with advanced solid tumours (English)
    0 references
    1932-1944
    0 references